Physician profile
Laura J Moore
NPI 1295767374
$1,229.99
in general payments reported to CMS, 2019-2025
11 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.25 · 2020: $35.21 · 2021: $69.38 · 2022: $72.02 · 2023: $112 · 2024: $250 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $707.04 | 2019-2025 | Nucala |
| Intuitive Surgical, INC. | $252.56 | 2025 | |
| Lilly USA, LLC | $56.20 | 2024-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $44.80 | 2025 | Freestyle Libre 3 |
| Aroa Biosurgery Incorporated | $42.41 | 2022 | |
| Abbvie INC. | $31.92 | 2021-2025 | |
| Ucb, INC. | $30.87 | 2025 | Briviact |
| Biogen, INC. | $26.16 | 2025 | Spinraza |
| Genentech USA, INC. | $22.21 | 2024 | Evrysdi |
| Tela Bio, INC. | $15.82 | 2024 | Ovitex 2s |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.